196 related articles for article (PubMed ID: 27775078)
1. Loss of CYLD expression unleashes Wnt signaling in multiple myeloma and is associated with aggressive disease.
van Andel H; Kocemba KA; de Haan-Kramer A; Mellink CH; Piwowar M; Broijl A; van Duin M; Sonneveld P; Maurice MM; Kersten MJ; Spaargaren M; Pals ST
Oncogene; 2017 Apr; 36(15):2105-2115. PubMed ID: 27775078
[TBL] [Abstract][Full Text] [Related]
2. Loss of the tumor suppressor CYLD enhances Wnt/beta-catenin signaling through K63-linked ubiquitination of Dvl.
Tauriello DV; Haegebarth A; Kuper I; Edelmann MJ; Henraat M; Canninga-van Dijk MR; Kessler BM; Clevers H; Maurice MM
Mol Cell; 2010 Mar; 37(5):607-19. PubMed ID: 20227366
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of LEF1 Impairs Myeloma Cell Growth Through Modulating CYLD/NF-κB Signaling.
Zhang G; Miao F; Liu K; Wu J; Xu J
Technol Cancer Res Treat; 2021; 20():15330338211034270. PubMed ID: 34269120
[TBL] [Abstract][Full Text] [Related]
4. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.
Annunziata CM; Davis RE; Demchenko Y; Bellamy W; Gabrea A; Zhan F; Lenz G; Hanamura I; Wright G; Xiao W; Dave S; Hurt EM; Tan B; Zhao H; Stephens O; Santra M; Williams DR; Dang L; Barlogie B; Shaughnessy JD; Kuehl WM; Staudt LM
Cancer Cell; 2007 Aug; 12(2):115-30. PubMed ID: 17692804
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of CYLD downregulation in breast cancer.
Hayashi M; Jono H; Shinriki S; Nakamura T; Guo J; Sueta A; Tomiguchi M; Fujiwara S; Yamamoto-Ibusuki M; Murakami K; Yamashita S; Yamamoto Y; Li JD; Iwase H; Ando Y
Breast Cancer Res Treat; 2014 Feb; 143(3):447-57. PubMed ID: 24398777
[TBL] [Abstract][Full Text] [Related]
6. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.
Keats JJ; Fonseca R; Chesi M; Schop R; Baker A; Chng WJ; Van Wier S; Tiedemann R; Shi CX; Sebag M; Braggio E; Henry T; Zhu YX; Fogle H; Price-Troska T; Ahmann G; Mancini C; Brents LA; Kumar S; Greipp P; Dispenzieri A; Bryant B; Mulligan G; Bruhn L; Barrett M; Valdez R; Trent J; Stewart AK; Carpten J; Bergsagel PL
Cancer Cell; 2007 Aug; 12(2):131-44. PubMed ID: 17692805
[TBL] [Abstract][Full Text] [Related]
7. Subquinocin, a small molecule inhibitor of CYLD and USP-family deubiquitinating enzymes, promotes NF-κB signaling.
Yamanaka S; Sato Y; Oikawa D; Goto E; Fukai S; Tokunaga F; Takahashi H; Sawasaki T
Biochem Biophys Res Commun; 2020 Mar; 524(1):1-7. PubMed ID: 31898971
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of CYLD as a trigger for NF-κB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells.
Urbanik T; Köhler BC; Boger RJ; Wörns MA; Heeger S; Otto G; Hövelmeyer N; Galle PR; Schuchmann M; Waisman A; Schulze-Bergkamen H
Int J Oncol; 2011 Jan; 38(1):121-31. PubMed ID: 21109933
[TBL] [Abstract][Full Text] [Related]
9. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members.
Trompouki E; Hatzivassiliou E; Tsichritzis T; Farmer H; Ashworth A; Mosialos G
Nature; 2003 Aug; 424(6950):793-6. PubMed ID: 12917689
[TBL] [Abstract][Full Text] [Related]
10. Dishevelled proteins and CYLD reciprocally regulate each other in CML cell lines.
Çalışkan C; Pehlivan M; Yüce Z; Sercan O
Mol Biol Rep; 2017 Oct; 44(5):391-397. PubMed ID: 28840581
[TBL] [Abstract][Full Text] [Related]
11. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma.
Jenner MW; Leone PE; Walker BA; Ross FM; Johnson DC; Gonzalez D; Chiecchio L; Dachs Cabanas E; Dagrada GP; Nightingale M; Protheroe RK; Stockley D; Else M; Dickens NJ; Cross NC; Davies FE; Morgan GJ
Blood; 2007 Nov; 110(9):3291-300. PubMed ID: 17609426
[TBL] [Abstract][Full Text] [Related]
12. [Research progress of deubiquitinating enzyme CYLD to regulate liver-related diseases].
Yang X; An DJ; Gao CC; Qin HY
Zhonghua Gan Zang Bing Za Zhi; 2019 Jun; 27(6):477-480. PubMed ID: 31357769
[TBL] [Abstract][Full Text] [Related]
13. Expression of CYLD and NF-kappaB in human cholesteatoma epithelium.
Byun JY; Yune TY; Lee JY; Yeo SG; Park MS
Mediators Inflamm; 2010; 2010():796315. PubMed ID: 20414373
[TBL] [Abstract][Full Text] [Related]
14. CYLD: a multifunctional deubiquitinase.
Glittenberg M; Ligoxygakis P
Fly (Austin); 2007; 1(6):330-2. PubMed ID: 18820455
[TBL] [Abstract][Full Text] [Related]
15. Rare occurrence of biallelic CYLD gene mutations in classical Hodgkin lymphoma.
Schmidt A; Schmitz R; Giefing M; Martin-Subero JI; Gesk S; Vater I; Massow A; Maggio E; Schneider M; Hansmann ML; Siebert R; Küppers R
Genes Chromosomes Cancer; 2010 Sep; 49(9):803-9. PubMed ID: 20607853
[TBL] [Abstract][Full Text] [Related]
16. SPATA2 promotes CYLD activity and regulates TNF-induced NF-κB signaling and cell death.
Schlicher L; Wissler M; Preiss F; Brauns-Schubert P; Jakob C; Dumit V; Borner C; Dengjel J; Maurer U
EMBO Rep; 2016 Oct; 17(10):1485-1497. PubMed ID: 27458237
[TBL] [Abstract][Full Text] [Related]
17. Wnt/β‑catenin signaling is a novel therapeutic target for tumor suppressor CYLD‑silenced glioblastoma cells.
Kanemaru A; Ito Y; Yamaoka M; Shirakawa Y; Yonemaru K; Miyake S; Ando M; Ota M; Masuda T; Mukasa A; Li JD; Saito H; Hide T; Jono H
Oncol Rep; 2023 Nov; 50(5):. PubMed ID: 37772388
[TBL] [Abstract][Full Text] [Related]
18. Mutated cylindromatosis gene affects the functional state of dendritic cells.
Bros M; Dexheimer N; Besche V; Masri J; Trojandt S; Hövelmeyer N; Reissig S; Massoumi R; Grabbe S; Waisman A; Reske-Kunz AB
Eur J Immunol; 2010 Oct; 40(10):2848-57. PubMed ID: 20836156
[TBL] [Abstract][Full Text] [Related]
19. Loss of CYLD might be associated with development of salivary gland tumors.
Fukuda M; Hiroi M; Suzuki S; Ohmori Y; Sakashita H
Oncol Rep; 2008 Jun; 19(6):1421-7. PubMed ID: 18497946
[TBL] [Abstract][Full Text] [Related]
20. Reduced expression of CYLD in human colon and hepatocellular carcinomas.
Hellerbrand C; Bumes E; Bataille F; Dietmaier W; Massoumi R; Bosserhoff AK
Carcinogenesis; 2007 Jan; 28(1):21-7. PubMed ID: 16774947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
